

Standard Orders for Actemra Administration

Patient _____ DOB _____ ACCT _____ Date _____

INDICATION:

<input type="checkbox"/> M05.79 RA w/ rheumatoid factor of multiple sites w/o organ involvement	<input type="checkbox"/> M06.09 RA w/o rheumatoid factor, multiplisites	<input type="checkbox"/> Other: _____
--------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------	----------------------------------------------

HISTORY:

- | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> MUST have had inadequate response to DMARD _____
<input type="checkbox"/> Rapid 3 _____
<input type="checkbox"/> ESR _____ | <input type="checkbox"/> Unable to tolerate DMARDS
<input type="checkbox"/> Swollen/tender joints |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|

Standard Order Protocol

- Confirm current Tspot or CXR ; Confirm HbsAg negative
- Obtain patient weight each visit
- Evaluate patient for active infections, prior or upcoming surgical procedures, medication allergies, history of liver disease, history of diverticulitis, or any other current health concerns as noted on Infusion Record
- Normal Saline Flush KVO before infusion. After primary drug has infused, 10 ml normal saline to flush tubing/line
- Vital signs every 30 minutes beginning with start of infusion
- **If infusion reaction occurs, slow or stop infusion, and initiate infusion reaction protocol.**
- Discharge instructions to include possible infusion side effects and follow up appointment schedule

DOSAGE: Tocilizumab (Actemra) IV infusion should be administered over 60 minutes or greater as tolerated every 4 weeks.

- Tocilizumab (Actemra) **4mg/kg** in 100ml Normal Saline IV
- Tocilizumab (Actemra) **8mg/kg** in 100ml Normal Saline IV

LABS: Should be verified as current (within 60 days) and within normal limits prior to each infusion

**DO NOT INITIATE THERAPY IF:	ANC < 2000 cells/mm³	Platelets < 100,000mm³	ALT/AST > 1.5x UNL
--------------------------------------	-------------------------------------------	---------------------------------------------	------------------------------

Standard Lab Protocol

- CBC w/ diff and Platelets at weeks 4 and 8; then every 12 weeks
- CMP 14 at weeks 4 and 8; then every 12 weeks
- Lipid Panel at week 8; then every 6 months as maintenance

Neutrophils (cells/mm ³)	During treatment with Actemra
ANC > 1000	Maintain dose
ANC 500 to 1000	Interrupt Actemra dosing When ANC > 1000 cells/mm ³ resume Actemra at 4mg/kg and increase to 8mg/kg as clinically appropriate
ANC < 500	Discontinue Actemra

Platelets	During treatment with Actemra
50,000 to 100,000	Interrupt Actemra dosing When platelet count is > 100,000 cells/mm ³ resume Actemra at 4mg/kg and increase to 8mg/kg as clinically appropriate
< 50,000	Discontinue Actemra

ALT/AST	During treatment with Actemra
> 1.5 to 3x UNL	Reduce Actemra dose to 4mg/kg or interrupt dose until lab values normalize
> 3 to 5x UNL	Interrupt dosing until <3x UNL and follow reccomendations for > 1.5 to 3x UNL
> 5x UNL	Discontinue Actemra

Additional orders/comments

Print Physician Name _____

Physician Signature _____

Date _____

Practice Name: _____

NPI: _____